Australia Cytomegalovirus Therapeutics Market Analysis

Australia Cytomegalovirus Therapeutics Market Analysis Summary

Australia Cytomegalovirus Therapeutics Market is valued at around $0.006 Mn in 2022 and is projected to reach $0.01 Mn by 2030, exhibiting a CAGR of 7.6% during the forecast period 2023-2030.

The widespread virus cytomegalovirus (CMV) can cause severe end-organ dysfunction in immunocompromised patients with congenital CMV illness, or it might be asymptomatic in healthy individuals. The herpesvirus family, Herpesviridae, or human herpesvirus-5, includes the human cytomegalovirus (HHV-5). Salivary glands and human cytomegalovirus infections are frequently linked. CMV infections may not cause any symptoms in healthy individuals, but they can be fatal in immunocompromised patients. Immunocompromised patients can develop a wide range of clinical illnesses from CMV, such as febrile syndromes, hepatitis, pneumonitis, retinitis, encephalopathy, esophagitis, and colitis.

The rise in the frequency of cytomegalovirus infection, investments in research & development, and the introduction of novel medicines are the main drivers of market growth for cytomegalovirus infection. In addition to Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, MEMO Therapeutics, Lion TCR, and others, there are other significant in Cytomegalovirus Therapeutics market.

Market dynamics

Market Development

According to Takeda, Livtencity, or maribavir, has been approved by the FDA for use in patients 12 years of age and older who have post-transplant cytomegalovirus (CMV) infection and are resistant to one of four available medications. Takeda estimates that out of the 200,000 adult transplants performed each year around the world, roughly 25% of transplant recipients may get CMV infections. A peak sales estimate of $700 million to $800 million for Livtencity has been made by the Japanese pharmaceutical company using those numbers.

A leading Phase III programme for Cytomegalovirus (HHV-5) Infections has been developed for MRNA-1647, an M-RNA vaccine sold by Moderna. Preventing Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients is a New Indication for PREVYMIS® (letermovir), a drug manufactured by Merck.

Market Drivers

Rise in the prevalence of cytomegalovirus infection

The market's growth rate between 2022 and 2030 is mostly driven by the rising prevalence of CMV infection. According to the Centers for Disease Control and Prevention, one in every 150 infants in the US is born with congenital cytomegalovirus (CMV) infection. Only one in five newborns who develop CMV go on to have long-term health problems. Due to increased infection rates and demand for better treatment options, the market for CMV infection treatment and diagnosis will grow.

Growing prevalence of viral infections

As AIDS patients' immune systems deteriorate, the prevalence of viral infections among them rises, increasing the requirement for anti-cytomegalovirus medications. In 2017, the CDC reported that 36.7 million persons worldwide were infected with the human immunodeficiency virus (HIV). It is anticipated that the availability of antiviral drugs to treat this ailment would increase demand for efficient treatment alternatives. This will affect how quickly the market expands.

Increase in the number of research and development activities      

In the upcoming years, it is predicted that the growing number of research and development initiatives for novel indications and the patent expiration of biologics would present new chances for the expansion of the cytomegalovirus market. Major institutes have started a number of projects centred on R&D initiatives related to CMV infection. For instance, in August 2019, the University of Washington's Program for Advanced Cell Therapy (PACT) began a pioneering cell-therapy trial for kidney transplant patients, using virus-specific white blood cells to treat patients with severe cytomegalovirus (CMV) infection following kidney transplantation.

Other drivers

Furthermore, the market for CMV will grow because of people's sedentary lifestyles and the increasing number of government campaigns to raise awareness. Along with this, growing healthcare costs and patent expirations that result in the availability of generic pharmaceuticals will accelerate the market's growth pace. Additionally, it is predicted that an increase in organ transplantation around the globe will accelerate market growth.

Market Restraints

The market for CMV treatments is being hampered by falling transplant rates and declining CMV prevalence brought on by highly active antiretroviral therapy (HAART). Cryotherapy and laser therapy are a couple of the alternatives that compete for market share.

The high price of the treatment, on the other hand, will limit the market's ability to expand. The cytomegalovirus market will face obstacles from a lack of healthcare facilities in emerging nations and a shortage of qualified workers. During the projection period of 2022–2030, lack of public awareness and drug side effects would also act as a restraint and limit market expansion.

This cytomegalovirus industry research contains information on the latest trends, trade laws, import-export analysis, production analysis, value chain optimization, market share, and the effects of domestic and international factors.